Jordyn Silverstein, MD, is a hematology/oncology fellow at UCLA Health. 

Dr Silverstein on the Efficacy of Abemaciclib Plus Hormonal Therapy in Recurrent Low- or High-Grade Serous Ovarian Cancer  

“Patients [with low-grade serous ovarian cancer] are really benefiting from this combination. Putting the data into [perspective]…after these patients progress on single-agent hormonal therapy, [their options are limited to] further chemotherapy or MEK inhibitors, which are [both] toxic. We hope these data can support further study [of CDK4/6 inhibition plus hormonal therapy] in [this patient population].”

Jordyn Silverstein, MD, a hematology/oncology fellow at UCLA Health, discusses data from a study evaluating the efficacy of adding the CDK4/6 inhibitor abemaciclib (Verzenio) to hormonal therapy in patients with recurrent, low- or high-grade serous ovarian cancer or endometroid endometrial cancer.

Videos

Jordyn Silverstein, MD, discusses the efficacy of abemaciclib plus hormonal therapy in recurrent ovarian cancer or endometroid endometrial cancer.

Jordyn Silverstein, MD

Articles

Dr Silverstein on the Efficacy of Abemaciclib Plus Hormonal Therapy in Recurrent Low- or High-Grade Serous Ovarian Cancer